FY2023 Q1
Financial Results
Revenue

¥1,058.6B

+3.7% growth at CER
FY2023 Q1 Financial Results

Core Operating Profit

¥326.3B

-2.0% change at Constant Exchange Rate (CER) reflects product mix and investment in R&D and Data & Technology

Core Operating Profit Margin

30.8%

Reported Operating Profit

¥168.6B

+12.0% growth driven by Growth & Launch Products and currency effects
Core EPS

¥150  +0.3% at CER

Reported EPS

¥58  -15.4% change impacted by one-time gain in Finance Income in FY2022 Q1
Our extensive portfolio of Growth & Launch Products continued to drive growth.

40% Share of Total Revenue

+16.2% Growth at CER
Management Guidance at CER

Core Revenue: Low-single-digit % decline
Core Operating Profit: Low-10s % decline
Core EPS: Low-20s % decline

Core Revenue: ¥3,840.0B
Core Operating Profit: ¥1,015.0B
Core EPS: ¥434

Core operating profit expected to exceed ¥1tn despite loss of exclusivity and coronavirus vaccines impact
Forecasted annual dividend increase to ¥188
Per share annually

Adopted progressive dividend policy of increasing or maintaining dividend each year
This presentation contains forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda’s FY2023 Q1 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda’s FY2023 Q1 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/ ) for further information about Takeda’s Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.